Amphastar Pharmaceuticals (AMPH) Earning Somewhat Favorable Media Coverage, Report Finds

Media stories about Amphastar Pharmaceuticals (NASDAQ:AMPH) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Amphastar Pharmaceuticals earned a news impact score of 0.24 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 47.0948640959541 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Several equities analysts have recently commented on the company. BMO Capital Markets reiterated a “market perform” rating and set a $19.00 price objective (up from $17.00) on shares of Amphastar Pharmaceuticals in a research report on Tuesday, March 13th. BidaskClub upgraded Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, March 13th. Needham & Company LLC reiterated a “buy” rating and set a $24.00 price objective (up from $23.00) on shares of Amphastar Pharmaceuticals in a research report on Tuesday, March 13th. Wells Fargo reiterated a “buy” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, March 21st. Finally, Zacks Investment Research lowered Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, March 13th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $21.33.

How to Become a New Pot Stock Millionaire

Shares of Amphastar Pharmaceuticals stock opened at $19.01 on Friday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.85 and a current ratio of 2.79. The stock has a market cap of $887.15, a PE ratio of 50.03, a PEG ratio of 1.36 and a beta of 1.42. Amphastar Pharmaceuticals has a 12 month low of $13.15 and a 12 month high of $20.45.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Monday, March 12th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.07 by $0.03. The firm had revenue of $60.40 million for the quarter, compared to analyst estimates of $60.62 million. Amphastar Pharmaceuticals had a return on equity of 4.56% and a net margin of 1.88%. The company’s revenue was down 4.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.01 EPS. research analysts forecast that Amphastar Pharmaceuticals will post 0.63 EPS for the current year.

In related news, insider Jason B. Shandell sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 20th. The stock was sold at an average price of $19.43, for a total transaction of $388,600.00. Following the transaction, the insider now directly owns 251,372 shares in the company, valued at approximately $4,884,157.96. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO William J. Peters sold 19,801 shares of the firm’s stock in a transaction that occurred on Tuesday, March 13th. The stock was sold at an average price of $20.10, for a total value of $398,000.10. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 84,387 shares of company stock worth $1,659,763. 11.10% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: This article was first published by Ticker Report and is owned by of Ticker Report. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://www.tickerreport.com/banking-finance/3337537/amphastar-pharmaceuticals-amph-earning-somewhat-favorable-media-coverage-report-finds.html.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Financial Review: Carvana  versus Its Competitors
Financial Review: Carvana versus Its Competitors
Brokerages Set Callon Petroleum  PT at $16.42
Brokerages Set Callon Petroleum PT at $16.42
Analyzing Paychex  and Forrester Research
Analyzing Paychex and Forrester Research
Head to Head Contrast: Aspen Group  versus The Competition
Head to Head Contrast: Aspen Group versus The Competition
Contrasting Rogers  & AdvanSix
Contrasting Rogers & AdvanSix
SSLJ.Com  Downgraded by ValuEngine
SSLJ.Com Downgraded by ValuEngine


© 2006-2018 Ticker Report. Google+.